Cartesian Therapeutics In Share Price

NASDAQ: RNAC

Small Cap

$9.18

-0.42

(-4.38%)

as on September 18, 2025 at 1:29 am IST

$₹

Cartesian Therapeutics In Stock Performance

as on September 18, 2025 at 1:29 am IST

Day's Low
Day's High
$9.14
Day's Price Range
$10
$9.18
0.44%
Downside
8.93%
Upside
52 Week's Low
52 Week's High
$8.46
52-Week Price Range
$26.5
$9.18
7.84%
Downside
188.67%
Upside

Cartesian Therapeutics In share price movements today

Previous Close: $9.60
Open: $9.66
Volume: 322.5K
Day's Low - High: $9.14 - $10
52 Week Low - High: $8.46 - $26.5

Cartesian Therapeutics In Historical Returns

1 Month Return: -15.27 %
3 Month Return: -1.94 %
1 Year Return: -42.27 %
3 Year Return: 0 %
5 Year Return: 0 %

Cartesian Therapeutics In Stock Fundamentals & Key Indicators

Check Cartesian Therapeutics In market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$254.6M

EPS (TTM)

-1.11

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.07%

PE Ratio (TTM)

-1.36

Industry PE ratio

P/B Ratio

PEG Ratio

EBITDA

-77.9M

Revenue (TTM)

1.0M

Profit Margin

0.00%

Return On Equity TTM

11153900.00%

Cartesian Therapeutics In Stock Valuation

Track how Cartesian Therapeutics In P/E has moved over time to understand its valuation trends.

Cartesian Therapeutics In in the last 5 years

Overview
Trends

Lowest (0.00x)

September 17, 2025

Industry (0.00x)

September 17, 2025

Today (-1.36x)

September 17, 2025

Highest (0.00x)

September 17, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.36x

Cartesian Therapeutics In vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cartesian Therapeutics In with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Cartesian Therapeutics In	BUY	$254.6M	NA	-1.36	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Cartesian Therapeutics In Stock including INR - Dollar returns

The Cartesian Therapeutics In stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cartesian Therapeutics In investment value today

Current value as on today

₹59,800

Returns

₹40,200

(-40.2%)

Returns from Cartesian Therapeutics In Stock

₹44,799 (-44.8%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Cartesian Therapeutics In Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Cartesian Therapeutics In. Average target price of $36.43

Cartesian Therapeutics In Share Price Target

Get share price movements and forecasts by analysts on Cartesian Therapeutics In.

What analysts predicted

74.8%UPSIDE

Target Price

$36.43

Current Price

$9.18

Analyzed by

11 Analysts

Target

$36.43

Cartesian Therapeutics In target price $36.43, a slight upside of 74.8% compared to current price of $9.18. According to 11 analysts rating.

Cartesian Therapeutics In Stock's Interest Amongst Investors

Search interest for Cartesian Therapeutics In Stock has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:-44% versus previous 30 day period

Cartesian Therapeutics In Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	5	5	6	8	5	33	0	0	1	0
Gross Profit	5	4	6	8	5	33	0	0	1	0
Operating Income	-18	-18	-13	-36	-13	13	-17	-26	-21	-21
EBITDA	-20	-10	-7	-196	-56	14	-23	-9	-20	-21
Interest Expense	0	0	1	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	1	0
Income Before Tax	-21	-11	-9	-196	-56	13	-24	-9	-17	15
Income Tax Expense	1	0	1	-19	0	0	-	0	-	-
Net Income	-21	-11	-9	-177	-56	13	-24	-10	-17	15
Net Profit Margin	-364.82%	-216.94%	-137.41%	-2149.26%	-973.01%	41.37%	-6248.84%	1350.86%	-1610.00%	5330.87%

Cartesian Therapeutics In Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	6	8	0	0	6	16	85	110	26	38
Gross Profit	6	8	0	0	6	16	85	108	24	38
Operating Income	-25	-34	-63	-65	-52	-56	-4	14	-86	-43
EBITDA	-23	-34	-63	-62	-51	-65	-5	39	-235	-77
Interest Expense	0	1	1	1	1	1	2	3	2	-
Depreciation	-	-	0	0	2	0	1	1	0	1
Income Before Tax	-25	-36	-65	-65	-55	-68	-9	34	-238	-77
Income Tax Expense	0	0	0	0	1	1	15	0	-19	0
Net Income	-25	-36	-65	-65	-55	-68	-25	35	-219	-77
Net Profit Margin	-418.80%	-447.98%	-31556.04%	-7235.44%	-828.97%	-414.99%	-30.19%	31.94%	-844.91%	-198.97%

Cartesian Therapeutics In Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-11	-9	-177	-56	13	-24	-10	-17	15
Operating Cash Flow	-9	-9	-23	-15	-14	13	-7	-23	-17
Investing Cash Flow	0	-	6	0	-1	-6	0	-1	-2
Financing Cash Flow	-2	-24	14	43	0	124	0	-8	0
Change in Cash	-12	-34	-2	26	-15	131	-6	-32	-20

Cartesian Therapeutics In Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-36	-65	-65	-55	-68	-25	35	-219	-77
Operating Cash Flow	-19	-52	-59	-51	34	-60	-31	-51	-23
Investing Cash Flow	-22	-2	25	0	0	-17	-15	34	-8
Financing Cash Flow	67	66	0	105	14	52	39	-13	168
Change in Cash	25	11	-33	52	48	-24	-7	-29	135

Global Institutional Holdings in Cartesian Therapeutics In

Funds	Holdings
FMR Inc	9.02%
MPM Oncology Impact Management LP	3.05%
BlackRock Inc	2.59%
Siren, L.L.C.	2.17%
Vanguard Group Inc	1.94%

See all

Insights on Cartesian Therapeutics In

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -17.71M → 15.88M (in $), with an average increase of 211.5% per quarter
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, RNAC has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.9% return, outperforming this stock by 107.5%
NEGATIVE IMPACT
Price Dip
In the last 1 month, RNAC stock has moved down by -14.9%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.1M → 298.0K (in $), with an average decrease of 72.9% per quarter

About Cartesian Therapeutics In

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat

Organisation	Cartesian Therapeutics In
Headquarters	7495 New Horizon Way, Frederick, MD, United States, 21703
CEO	Dr. Carsten Brunn Ph.D.
E-voting on shares	Click here to vote

Key Management of Cartesian Therapeutics In

Name	Title
Dr. Carsten Brunn Ph.D.	President, CEO & Director
Mr. Blaine T. Davis	Chief Financial Officer
Dr. Chris Jewell Ph.D.	Chief Scientific Officer
Dr. Metin Kurtoglu M.D., Ph.D.	Consultant
Dr. Emily English Ph.D.	Chief Operating Officer
Mr. Matthew Bartholomae J.D.	General Counsel & Secretary
Dr. Milos Miljkovic M.D., Ph.D.	Chief Medical Officer

FAQs

What is Cartesian Therapeutics In share price today?

Cartesian Therapeutics In share price today is $9.18 as on September 18, 2025 at 1:29 am IST at the close of the market. Cartesian Therapeutics In share today touched a day high of $10 and a low of $9.14.

What is the 52 week high and 52 week low for Cartesian Therapeutics In share?

Cartesian Therapeutics In share touched a 52 week high of $26.5 on December 6, 2024 and a 52 week low of $8.46 on May 27, 2025. Cartesian Therapeutics In stock price today i.e. September 18, 2025 at 1:29 am IST is closed at $9.18,which is 65.36% down from its 52 week high and 8.51% up from its 52 week low.

What is Cartesian Therapeutics In's market capitalisation today?

Cartesian Therapeutics In market capitalisation is $0.00T as on September 18, 2025 at 1:29 am IST.

How to invest in Cartesian Therapeutics In Stock (RNAC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cartesian Therapeutics In on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cartesian Therapeutics In Shares that will get you 0.1634 shares as per Cartesian Therapeutics In share price of $9.18 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cartesian Therapeutics In Stock (RNAC) from India?

Indian investors can start investing in Cartesian Therapeutics In (RNAC) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 10:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Cartesian Therapeutics In stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 10:39 am IST). Based on Cartesian Therapeutics In share’s latest price of $9.18 as on September 18, 2025 at 1:29 am IST, you will get 1.0893 shares of Cartesian Therapeutics In. Learn more about fractional shares .